S1 Supplemental methods

Receiving Only 1 Dose of a 2-Dose Primary Series. S2 Supplemental methods: Quantitative Bias Analysis for Exposure Misclassification. S1 Table. IIS Jurisdictions and Study Periods Utilized. S2 Table. Details of Follow-up for the Complete Primary Vaccination Series Exposure Patterns. S3 Table. Characteristics of Adults Aged 18-64 Years Vaccinated With BNT162b2 COVID-19 Vaccine and Matched Unvaccinated Comparators. S4 Table. Characteristics of Adults Aged 18-64 Years Vaccinated With an mRNA 1273 COVID-19 Vaccine and Matched Unvaccinated Comparators. S5 Table. Characteristics of Adults Aged 18-64 Years Vaccinated With JNJ-7836735 COVID-19 Vaccine and Matched Unvaccinated Comparators. S6 Table. Estimated Effectiveness of Receiving a Complete Primary Series of COVID-19 Vaccine in Adults Aged 18-64 Years, Compared With Being Unvaccinated, Overall. S7 Table. Estimated Effectiveness of Receiving a Complete Primary Series of COVID-19 Vaccine in Adults Aged 18-64 Years, Compared With Being Unvaccinated, by Previous COVID-19 Diagnosis Status. S8 Table. Estimated Effectiveness of Receiving a Complete Primary Series of COVID-19 Vaccine Compared with Being Unvaccinated, Corrected for Potentially Missing Vaccine Records. S9 Table. Estimated Effectiveness of Receiving a Complete Primary Series of COVID-19 Vaccine Compared With Being Unvaccinated, Over Time. S1 Fig.Propensity Score Distributions of Adults Aged 18-64 Years Receiving a Complete Primary Series of COVID-19 Vaccine and Matched Unvaccinated Comparators. S2 Fig.Estimated Effectiveness of Receiving a Complete Primary Series of COVID-19 Vaccine in Adults Aged 18-64 Years, Compared With Being Unvaccinated, Overall and Within Subgroups. S3 Fig.Estimated Effectiveness of Receiving a Complete Primary Series of COVID-19 Vaccine in Adults Aged 18-64 Years, Compared With Being Unvaccinated, Primary and Sensitivity Analyses. S4 Fig.Weighted Cumulative Incidence of COVID‑19 Outcomes in Adults Aged 18-64 Years Receiving a Complete Primary Series of COVID-19 Vaccines and Matched Unvaccinated Comparators. S5 Fig. Cumulative Incidence of COVID 19 Outcomes in Adults Receiving a Complete Primary Series of COVID-19 Vaccines and Matched Unvaccinated Comparators, Negative Control Outcome in the First 14 Days. S6 Fig.Estimated Effectiveness of Receiving a Complete Primary Series of COVID-19 Vaccine in Adults Aged 18-64 Years, Compared With Being Unvaccinated, by SARS-CoV-2 Variant Era. S7 Fig. Estimated Relative Effectiveness of Receiving a Complete Primary Series of COVID-19 Vaccine in Adults Aged 18-64 Years, Compared With Receiving a Complete Primary Series of Different COVID-19 Vaccines. S8 Fig. Estimated Effectiveness of Receiving a Single Dose of a 2-Dose Primary Series of COVID-19 Vaccine in Adults Aged 18‑64 Years, Compared With Being Unvaccinated. S9 Fig.Weighted Cumulative Incidence of COVID‑19 Outcomes in Adults Aged 18-64 Years Receiving a Single Dose of a 2-Dose Primary Series of COVID-19 Vaccine and Matched Unvaccinated Comparators.

(DOCX)